BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 33298062)

  • 21. Glycopyrrolate/formoterol (Bevespi Aerosphere) for COPD.
    Med Lett Drugs Ther; 2016 Oct; 58(1505):130-132. PubMed ID: 27701364
    [No Abstract]   [Full Text] [Related]  

  • 22. Ethnic Sensitivity Study of the Extrafine, Single-Inhaler, Triple Therapy Beclomethasone Dipropionate, Formoterol Fumarate, and Glycopyrronium Bromide Pressurized Metered Dose Inhaler in Japanese and Caucasian Healthy Individuals: A Randomized, Double-Blind, Single-Dose Crossover Study.
    Cella M; Täubel J; Delestre-Levai I; Tulard A; Vele A; Georges G
    Clin Ther; 2021 Nov; 43(11):1934-1947.e4. PubMed ID: 34600734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of glycopyrronium/formoterol fumarate dihydrate delivered via metered dose inhaler using co-suspension delivery technology in patients with moderate-to-very severe COPD.
    Ferguson GT; Rodriguez-Roisin R; Reisner C; Maes A; Siddiqui S; Martin UJ
    Int J Chron Obstruct Pulmon Dis; 2018; 13():945-953. PubMed ID: 29606861
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of beclometasone dipropionate/formoterol extra-fine fixed combination on the peripheral airway inflammation in controlled asthma.
    Bulac S; Cimrin A; Ellidokuz H
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):82-7. PubMed ID: 25050594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study.
    D'Urzo AD; Rennard SI; Kerwin EM; Mergel V; Leselbaum AR; Caracta CF;
    Respir Res; 2014 Oct; 15(1):123. PubMed ID: 25756831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extrafine triple therapy and asthma exacerbation seasonality: TRIMARAN and TRIGGER post hoc analyses.
    Papi A; Virchow JC; Singh D; Kots M; Vele A; Georges G; Canonica GW
    J Allergy Clin Immunol; 2021 Jul; 148(1):262-265.e2. PubMed ID: 33485959
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy And Safety Of Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler (GFF MDI) Formulated Using Co-Suspension Delivery Technology In Chinese Patients With COPD.
    Chen R; Zhong N; Wang HY; Zhao L; Mei X; Qin Z; Huang J; Assam PN; Maes A; Siddiqui S; Martin UJ; Reisner C
    Int J Chron Obstruct Pulmon Dis; 2020; 15():43-56. PubMed ID: 32021143
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, seven-day study to assess the efficacy and safety of a glycopyrrolate/formoterol fumarate fixed-dose combination metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with moderate-to-very severe chronic obstructive pulmonary disease.
    Reisner C; Fabbri LM; Kerwin EM; Fogarty C; Spangenthal S; Rabe KF; Ferguson GT; Martinez FJ; Donohue JF; Darken P; St Rose E; Orevillo C; Strom S; Fischer T; Golden M; Dwivedi S
    Respir Res; 2017 Jan; 18(1):8. PubMed ID: 28061907
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
    Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
    Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
    Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide as a combination therapy for chronic obstructive pulmonary disease.
    Kupczyk M; Kuna P
    Expert Rev Respir Med; 2019 Jan; 13(1):5-11. PubMed ID: 30463457
    [TBL] [Abstract][Full Text] [Related]  

  • 33. An Open-Label Study Evaluating the Performance of the Dose Indicator in a Metered Dose Inhaler Delivering Glycopyrrolate and Formoterol Fumarate in Patients with Moderate-to-Very Severe Chronic Obstructive Pulmonary Disease.
    Pudi K; Feldman G; Fakih F; Mack P; Maes A; Siddiqui S; St Rose E; Reisner C
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):40-46. PubMed ID: 30335559
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The impact of indacaterol/glycopyrronium fixed-dose combination versus tiotropium monotherapy on lung function and treatment preference: a randomized crossover study - the FAVOR study.
    Kardos P; Hagedorn-Peinz I
    Int J Chron Obstruct Pulmon Dis; 2018; 13():69-77. PubMed ID: 29317812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD.
    Rabe KF; Martinez FJ; Ferguson GT; Wang C; Singh D; Wedzicha JA; Trivedi R; St Rose E; Ballal S; McLaren J; Darken P; Aurivillius M; Reisner C; Dorinsky P;
    N Engl J Med; 2020 Jul; 383(1):35-48. PubMed ID: 32579807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized study of the effects of Aerochamber Plus
    Fakih F; Spangenthal S; Sigal B; Darken P; Maes A; Siddiqui S; Gillen M; Reisner C; Martin UJ
    Respir Med; 2018 May; 138():74-80. PubMed ID: 29724397
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
    Singh D; Vezzoli S; Petruzzelli S; Papi A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Triple Therapy with Budesonide/Glycopyrrolate/Formoterol Fumarate Improves Inspiratory Capacity in Patients with Asthma-Chronic Obstructive Pulmonary Disease Overlap.
    Ishiura Y; Fujimura M; Ohkura N; Hara J; Kasahara K; Ishii N; Sawai Y; Shimizu T; Tamaki T; Nomura S
    Int J Chron Obstruct Pulmon Dis; 2020; 15():269-277. PubMed ID: 32103926
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of beclomethasone/formoterol fixed combination on lung hyperinflation and dyspnea in COPD patients.
    Tzani P; Crisafulli E; Nicolini G; Aiello M; Chetta A; Clini EM; Olivieri D
    Int J Chron Obstruct Pulmon Dis; 2011; 6():503-9. PubMed ID: 22069361
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized controlled trial of triple versus dual inhaler therapy on small airways in smoking asthmatics.
    Jabbal S; Kuo CR; Lipworth B
    Clin Exp Allergy; 2020 Oct; 50(10):1140-1147. PubMed ID: 33180376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.